Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

ECOR vs PRPO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PRPO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)

PRPO Overall Winner 6-Pillar Tally: ECOR 1 – 4 PRPO (1 Tie) Matrix Metrics: ECOR 4 – 6 PRPO

As of Nov 19, 2026, Precipio, Inc. (PRPO) is the stronger overall head-to-head candidate over electroCore, Inc. (ECOR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ECOR carries a Unified Composite Score of 56.8/100 (HOLD) at $4.85 (N/M Forward P/E, -33.1% operating margin), whereas PRPO carries 51.3/100 (HOLD) at $18.49 (15.4x Forward P/E, -5.3% operating margin).

  • Composite vs. Pillar Nuance: While ECOR currently prints a higher short-term Unified Composite Score (56.8/100 HOLD vs. PRPO 51.3/100 HOLD), PRPO captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-5.3% vs. -33.1% operating margin) and revenue trajectory (+8.3% vs. +11.5% YoY).
  • Technical & Structure Timing Caution: ECOR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5); meanwhile PRPO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ECOR vs PRPO
ECOR NASDAQ
electroCore, Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.85
-6.19% 1D
Market Cap $47.7M
TTM Revenue $38M
Forward P/E N/M
Beta / 30D Vol 1.52β · 155% Vol
Unified Composite Score
56.8 / 100 HOLD
Tech 68.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.5%), weak momentum, RSI 32
RSI-14: 31.5 · SMA20: $6.90 · SMA50: $8.67
PRPO NASDAQ Head-to-Head Winner
Precipio, Inc. Common Stock
Laboratory Analytical Instruments
$18.49
-1.44% 1D
Market Cap $34.6M
TTM Revenue $28M
Forward P/E 15.4x
Beta / 30D Vol 1.26β · 96% Vol
Unified Composite Score
51.3 / 100 HOLD
Tech 55.0 Fund 54.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.8%), weak momentum, RSI 40
RSI-14: 40.1 · SMA20: $20.00 · SMA50: $22.35

6-Pillar Scorecard Institutional Category Breakdown (ECOR 1 – 4 PRPO)

Columns: Metric · ECOR · PRPO
1. Valuation Multiples PRPO
Forward P/E N/M 15.4x
Trailing P/E N/M 15.4x
PEG Ratio N/M N/M
EV / Revenue 1.4x 1.2x
2. Growth & Scale ECOR
Revenue Growth (YoY) +11.5% +8.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $38M $28M
Market Cap $47.7M $34.6M
3. Profitability & Quality PRPO
Gross Margin 87.7% 44.6%
Operating Margin -33.1% -5.3%
Net Profit Margin -33.5% -4.1%
Return on Equity (ROE) -478.7% -8.0%
4. Balance Sheet & Cash Flow PRPO
Cash Generation (TTM) -$6.9M -$56,000 EBITDA
Cash Flow Margin -18.1% -0.2% EBITDA Mgn
Net Cash / Leverage $4.6M Net Debt $8.29 Book/Sh · -8.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat PRPO
OpEx & R&D Intensity N/A 49.9% of Rev ($14M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ECOR (4) vs PRPO (6)
Institutional Metric ECOR PRPO Criterion Row Edge
Market Capitalization
Scale
$47.7M $34.6M Larger Scale ECOR
Trailing P/E Ratio
Valuation
N/M 15.4x Lower Multiple PRPO
Forward P/E Ratio
Valuation
N/M 15.4x Lower Multiple PRPO
Revenue Growth (YoY)
Growth
+11.5% +8.3% Higher Growth ECOR
Operating Margin (TTM)
Profitability
-33.1% -5.3% Higher Margin PRPO
Net Profit Margin
Profitability
-33.5% -4.1% Higher Margin PRPO
Return on Equity (ROE)
Capital Efficiency
-478.7% -8.0% Higher ROE PRPO
52-Week Range Position
Momentum
6% ($4–$13) 4% ($18–$34) Stronger Trend ECOR
Beta / 30D Volatility
Risk Regime
1.52β · 155% Vol 1.26β · 96% Vol Lower Realized Risk PRPO
Unified Institutional Score
Composite Signal
56.8 / 100 (HOLD) 51.3 / 100 (HOLD) Higher Composite ECOR
Trailing 12M Revenue (USD)
Operating Scale
$38M $28M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.7% 44.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.4x EV/Rev N/M PEG · 1.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$6.9M ($4.6M Net Debt) -$56,000 EBITDA ($8.29 Book/Sh · -8.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PRPO +21.02 pp
ECOR: -34.01% · PRPO: -12.99%
3M Horizon PRPO +14.62 pp
ECOR: -53.9% · PRPO: -39.28%
6M Horizon ECOR +5.68 pp
ECOR: -19.03% · PRPO: -24.71%
1Y Horizon ECOR +16.96 pp
ECOR: -3.96% · PRPO: -20.92%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ECOR vs PRPO. Trailing 12-month operating profitability (ECOR -33.1% vs PRPO -5.3%) and valuation multiples (ECOR N/M vs PRPO 15.4x Forward P/E) are benchmarked directly in Pillar 4 below.

ECOR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$38M
Gross Margin87.7%
Op. Margin-33.1%
ROE / Fwd P/E-478.7% · N/M
PRPO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$28M
Gross Margin44.6%
Op. Margin-5.3%
ROE / Fwd P/E-8.0% · 15.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ECOR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ECOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PRPO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PRPO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ECOR Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $47.7M market capitalization and -33.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PRPO Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $34.6M market capitalization and -5.3% operating margin.
OpEx & R&D Reinvestment 49.9% of Rev ($14M)
90D Engineering Disclosures 0 Published

Investor FAQ ECOR vs PRPO Key Questions & Quantitative Answers

As of Nov 19, 2026, Precipio, Inc. (PRPO) is the stronger overall head-to-head candidate over electroCore, Inc. (ECOR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ECOR carries a Unified Composite Score of 56.8/100 (HOLD) at $4.85 (N/M Forward P/E, -33.1% operating margin), whereas PRPO carries 51.3/100 (HOLD) at $18.49 (15.4x Forward P/E, -5.3% operating margin). Composite vs. Pillar Nuance: While ECOR currently prints a higher short-term Unified Composite Score (56.8/100 HOLD vs. PRPO 51.3/100 HOLD), PRPO captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-5.3% vs. -33.1% operating margin) and revenue trajectory (+8.3% vs. +11.5% YoY). Technical & Structure Timing Caution: ECOR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5); meanwhile PRPO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ECOR leads the Growth & Scale pillar: ECOR posts +11.5% YoY revenue growth and +0.0% YoY earnings growth on $38M TTM revenue (87.7% gross margin, -33.1% operating margin), compared with PRPO at +8.3% YoY revenue growth and +0.0% YoY earnings growth on $28M TTM revenue (44.6% gross margin, -5.3% operating margin). On trailing 12-month operating scale, ECOR generates $38M in USD-normalized revenue versus $28M for PRPO. In operating R&D and SG&A reinvestment, ECOR deploys N/A (0 90-day corporate R&D disclosures) versus 49.9% of Rev ($14M) (0 disclosures) for PRPO.

PRPO screens cheaper on headline valuation multiples. ECOR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.4x EV/Revenue (-18.1% FCF margin), whereas PRPO trades at 15.4x Forward P/E, 15.4x Trailing P/E, N/M PEG, and 1.2x EV/Revenue (-0.2% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ECOR (-478.7% ROE) versus PRPO (-8.0% ROE) capital efficiency.

In options market volatility and institutional positioning, ECOR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 155% Vol realized risk). By comparison, PRPO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.26β · 96% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.